Table 2.

Univariate and multivariable analysis of risk factors for clinical outcomes of allogeneic stem cell transplantation.

Covariate	Univariate analysis			Multivariate analysis
	HR	95% CI	P	HR	95% CI	P
GRADE I–IV aGVHD
NK dose: >2.19 vs. ≤ 2.19 × 107/kg	0.551	0.315–0.963	0.037
With ATG vs. without ATG	0.603	0.33–1.101	0.096
NK CD107a level: >20.5 vs. ≤ 20.5%	0.294	0.156–0.554	0.000	0.357	0.184–0.69	0.002
NKG2A + %NK: >25.5 vs. ≤ 25.5%	1.648	0.927–2.931	0.089
MFI-CD226 of NK: >3,589 vs. ≤ 3,589	0.492	0.231–1.048	0.066
MFI-NKG2D of NK: >2,491 vs. ≤ 2,491	0.471	0.257–0.862	0.015	0.384	0.285–0.721	0.003
GRADE III–IV aGVHD
MRD vs. Haplo	0.504	0.268–0.946	0.033
NK dose: >2.19 vs. ≤ 2.19 × 107/kg	0.428	0.173–1.055	0.094
NK CD107a level: >20.5 vs. ≤ 20.5%	0.102	0.024–0.445	0.002	0.13	0.029–0.595	0.009
NKG2A + %NK: >25.5 vs. ≤ 25.5%	3.368	1.372–8.355	0.008	3.627	1.466–0.026	0.005
MFI-NKG2D of NK: >2,491 vs. ≤ 2,491	0.403	0.145–1.123	0.082
CHRONIC GVHD
NK CD107a level: >20.5 vs. ≤ 20.5%	0.503	0.248–1.019	0.034
Non-aGVHD vs. aGVHD	2.134	1.065–4.279	0.033
RELAPSE
High risk	9.185	2.905–29.035	0.000	6.924	1.922–24.941	0.003
Donor NK CD107a level	0.157	0.035–0.696	0.015
OS
High risk	4.229	1.865–9.588	0.001	3.619	1.573–8.325	0.002
0–II aGVHD vs. III–IV aGVHD	0.124	0.038–0.405	0.002	2.934	1.253–6.870	0.013
NK CD107a level: >20.5 vs. ≤ 20.5%	0.355	0.14–0.895	0.028